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Objective: To explore the expression of HAX-1 mRNA and protein in esophageal squamous cell carcinoma (ESCC)
and its relation with the prognosis of patients with ESCC.
Methods: The expression of HAX-1 mRNA and protein were detected with quantitative real-time RT-PCR and
immunohistochemical method in 112 ESCC samples and 112 corresponding non-neoplastic samples. Survival curves were
made with follow-up data. The relations of the prognosis with clinical and pathological characteristics were analyzed.
Results: The expression level of HAX-1 mRNA and the strong positive rate of HAX-1 protein were significantly higher in
ESCC samples (0.527 ± 0.060 and 45.54%) than that in non-neoplastic samples (0.121 ± 0.017 and 0.00%), and in ESCC
samples with lymph node metastasis (0.554 ± 0.054 and 71.11%) than that in ESCC samples without lymph node
metastasis (0.509 ± 0.058 and 28.36%) (all P < 0.01). HAX-1 mRNA expression level was a risk factor of lymph node
metastasis in patients with ESCC (P = 0.000). There were significant differences in survival curves between lymph node
metastatic group and non-metastatic group (P = 0.000), and among groups of HAX-1 protein expression +, ++and +++
(,P = 0.000); but no statistical significance between male patients and female patients (P = 0.119), and between ≥60 years
old patients and <60 years old patients (P = 0.705). The level of HAX-1 mRNA (P = 0.000) and protein (P = 0.005) were risk
factors of survival, but lymph node metastasis (P = 0.477) was not.
Conclusion: There is HAX-1 over-expression in ESCC tissue and HAX-1 mRNA level is a risk factor of lymph node
metastasis. The level of HAX-1 mRNA and protein were risk factors of survival in patients with ESCC. HAX-1 may be a
novel therapeutic target for ESCC treatment.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5130393079296037
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HS1-associated protein X-1 (HAX-1) which can interact
with hematopoietic cell specific Lyn substrate 1 (HS1), a
Src kinase substrate involved in the maturation of T
cells, was originally identified by Suzuki et al. [1] with
yeast two-hybrid system in 1997. The human HAX-1
gene is located on chromosome 1 (1q21.3) [2]. HAX-1 is
ubiquitously expressed in murine and human tissues,
with the highest expression levels found in metabolically* Correspondence: zhaogq@zzu.edu.cn
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reproduction in any medium, provided the oractive tissues, particularly the skeletal and heart muscles,
followed by substantial but evidently lower levels in
brain and pancreas, whereas the kidney, liver, lung, and
placenta contained the least amounts. In addition to the
predominantly mitochondrial distribution, HAX-1 can
also be found at nuclear membrane and endoplasmic
reticulum [1].
HAX-1, as a kind of multifunctional protein, is in-
volved in a variety of important physiological and patho-
logical processes including anti-apoptosis, cell migration
and endocytosis, and combination with mRNA 3’un-
translated region (30UTR) [3-11]. HAX-1 is related to
genesis, invasion and metastasis of many tumors [12,13],
and is over-expressed in a variety of tumors [12,14,15]his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[17], lymphoma, melanoma [12], leukemia, myeloma,
breast cancer and hepatoma [18].
There is a high incidence of esophageal cancer in Henan
Province. To explore the role of HAX-1 in esophageal
squamous cell carcinoma (ESCC) and to provide a basis
for finding new anti-esophageal cancer drugs, we detected
the expression of HAX-1 mRNA and protein with real-
time RT-PCR and immunohistochemical method, and
made the survival analysis in 112 patients with ESCC.
Materials and methods
Patients and specimens
Between 2003 and 2005, 112 patients with ESCC were en-
rolled in this study from Tumor Hospital of Linzhou City,
Linzhou People’s Hospital and the First Affiliated Hospital
of Zhengzhou University. All the patients recruited to this
study had not received any chemoradiotherapy, radiother-
apy and immunotherapy directed against ESCC prior to
oesophagectomy. Of the 112 patients, 62 were female and
50 were male, with a mean age of (59.58 ± 8.57) years
(range 44–77). And there were 45 cases with lymph node
metastasis, 67 cases without lymph node metastasis. ESCC
and adjacent non-neoplastic samples (taken away from the
tumor edge over 5 cm) were collected from each patient.
Samples were quickly stored in liquid nitrogen for future
use. This study was approved by the ethics committee of
Zhengzhou University and informed consent was obtained
from each patient.
Primers
HAX-1 and β-actin primers were designed according
to HAX-1 mRNA (NM_006118) and β-actin mRNA
(NM_001101) with Oligo 6.0 software. The sequences
were as follows: HAX-1 sense 50-GACACTTCGGGA
CTCAATGCT-30, HAX-1 antisense 50-TAGGACTGCTA
TCTGCTTCGT-30, β-actin sense 50-CGGGACCTFACT
GACTACCTC-30, β-actin antisense 50-CAAGAAAGGG
TGTAACGCAAC- 30. The length of fragments amplified
by PCR with HAX-1 primers and β-actin primers were
380 bp and 618 bp, respectively. All the primers were syn-
thesized by Shanghai Biosune Biotechnology Company.
Real-time fluorescent quantitative RT-PCR
RNAs were extracted from 112 ESCC samples and 112
non-neoplastic samples with RNA extraction kit (Qiagen)
and then cDNAs were generated by AMV (Promega).
Real-time PCR was performed using SYBRW Green Real
time PCR Kit (TaKaRa). PCR cycling condition was set as
follows: an initial denaturing step at 95°C for 3 min and
35 cycles at 95°C for 20 s, 60°C for 60 s. CT value in each
tube was recorded to calculate gene copy number.
The housekeep gene, β-actin, was used as an internal
control and normalization analysis. The comparativeexpression levels were determined as a ratio between
HAX-1 and β-actin to correct for variation in the
amounts of mRNA.
Immunohistochemistry
112 ESCC samples and 112 non-neoplastic samples were
fixed with 10% neutral buffered formalin, embedded in
paraffin, and then sectioned. UltraSensitive™ SP kit
(Maxim-Bio, China) was employed for immunochemical
staining according to the manufacturer’s instructions.
Rabbit anti-HAX-1 antibodies (Santa Cruz) were applied
at 1:50 dilution. The sections were stained with
streptavidin peroxidase (SP) kit(Maixin Biotechnology
Company, China), visualized with DAB coloration kit
(Boaosen Company, China), followed by counterstaining
of campeachy, dehydration, transparency and mounting.
All slides were assessed by two observers independently
and then in conference in a blinded manner without any
prior knowledge of the clinicopathological parameters.
Negative controls of immunohistochemical reactions
were performed by omitting the primary antibody. Re-
placement of primary antibody by PBS was used as blank
control.
Immunostaining of each section was semiquantitatively
scored for intensity (0,absent;1,weak; 2, moderate; 3, strong)
and extent of staining (percentage of the positive tumor
cells: 0, ≤5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; 4, >75%). The
scoring results of intensity and extent were multiplied to
give a composite score ranging from 1 to 12 for each
section: 0,-(negtive); 1–4,+(weak positive); 5–8,++(moder-
ate positive); 9–12,+++(strong positive).
Follow-up and survival analysis
Patients were followed up. The overall survival period
was defined as the duration from the postoperative time
point to death time point. The follow-up deadline was
March 6, 2010. The median follow-up time was 53 -
months (range 8–84). Based on the follow-up data, the
survival curves were made. The relations of HAX-1 ex-
pression with age, sex and lymph node metastasis were
analyzed.
Statistical analysis
Statistical analysis was performed using SPSS13.0 soft-
ware. Data were expressed as (x  SD). Student’s t test
was used in the comparison of mean between two sam-
ples. Fourfold table Chi square test was used in the com-
parison of ratios between two samples. Logistic analysis
was used in the correlation of lymph node metastasis
with HAX-1 mRNA expression. The follow-up data was
analyzed by the Kaplan-Meier method and log-rank test.
Cox proportional hazards model were used in multivari-
ate prognostic analysis. P values less than 0.05 were con-
sidered statistically significant.
Table 1 Expressions of HAX-1 mRNA in ESCC samples (x  S)
Groups n HAX-1 mRNA P
Peri-cancerous samples 112 0.121 ± 0.017 P = 0.000
ESCC samples 112 0.527 ± 0.060
Age(yr)
≥60 50 0.537 ± 0.063 P = 0.101
<60 62 0.519 ± 0.057
Gender
Male 50 0.535 ± 0.060 P = 0.231
Female 62 0.521 ± 0.060
Lymph node metastasis
Yes 45 0.554 ± 0.054 P = 0.000
No 67 0.509 ± 0.058
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HAX-1 mRNA is over-expressed in ESCC samples and is a
risk factor of lymph node metastasis
The relative expression level of HAX-1 mRNA was signifi-
cantly higher in ESCC samples (112 samples, 0.527 ±
0.060) than that in non-neoplastic samples(112 corre-
sponding samples, 0.121 ± 0.017) (t = −69.347, P = 0.000),
and in ESCC samples with lymph node metastasis
(45 samples, 0.554 ± 0.054) than that in ESCC samples
without lymph node metastasis (67 samples, 0.509 ±
0.058) (t = 4.240, P = 0.000) (Table 1). Logistic regression
analysis indicated that the relative expression level of
HAX-1 mRNA was a risk factor of lymph node metastasis
in the patients with ESCC (Wald χ2 = 12.743, P = 0.000).
Strong positive rate of HAX-1 protein is high in ESCC
samples and associated with lymph node metastasis
HAX-1 showed positive immuno-reactivity mainly in
cytoplasms of the cells (Figure 1). The positive rate of
HAX-1 protein expression was 100% in ESCC samples
and corresponding non-neoplastic samples. The strong
positive rate of HAX-1 protein expression was significantly
higher in ESCC samples (45.54%, 51/112) than that in
non-neoplastic samples (0.00%, 0/112), and in ESCC sam-
ples with lymph node metastasis (71.11%, 32/45) than
that in ESCC samples without lymph node metastasisFigure 1 All the ESCC samples and non-neoplastic samples were fixed
then sectioned. Then immunohistochemistry was carried out. Figure 1A: H
HAX-1 staining is weakly positive in ESCC samples (400×); Figure 1C: HAX-1(28.36%, 19/67) (P < 0.05). There were no statistical differ-
ences between different sexes (male and female) and ages
(≥60 years and < years) (Table 2).
Expression level of HAX-1 mRNA and protein are risk
factors of survival in patients with ESCC
Survival curves were drawn using SPSS13.0 software with
Kaplan-Meier method. Log-rank test indicated that there
were significant differences in survival curves between
lymph node metastatic group and non-metastatic group
(χ2 = 19.484, P = 0.000, Figure 2A), and among groups of
HAX-1 protein expression +, ++ and +++(χ2 = 80.729,
P = 0.000, Figure 2B); but no significant differences be-
tween male patients and female patients (χ2 = 2.435,
P= 0.119, Figure 2C), and between ≥60 years old patients
and <60 years old patients (χ2 = 0.143, P = 0.705, Figure 2D).
COX-univariate regression analysis indicated that
lymph node metastasis (Wald χ2 = 17.967, P = 0.000), the
expression level of HAX-1 mRNA (Wald χ2 = 91.507,
P = 0.000) and the expression level of HAX-1 protein
(Wald χ2 = 54.714, P = 0.000) were risk factors of survival
in the patients with ESCC; but sex (Wald χ2 = 2.334, P =
0.127) and age (P = 0.711) were not risk factors of sur-
vival. Further COX-multivariate regression analysis indi-
cated that the level of HAX-1 mRNA(Wald χ2 = 55.641,
P = 0.000) and protein (Wald χ2 = 0.7.929, P = 0.005)
were risk factors of survival, but lymph node metastasis
(Wald χ2 = 0.506, P = 0.477) were not a risk factor of sur-
vival in the patients with ESCC.
Discussion
HAX-1, a kind of multifunctional protein, is recently dis-
covered [19]. It was first discovered in its interaction
with HS-1 (Src kinase substrate), suggesting that HAX-1
is involved in B cell signal transduction. HAX-1 is asso-
ciated with many cellular proteins and viral proteins,
suggesting that HAX-1 is involved in multifunctional
signaling pathways and cellular processes. The homology
between HAX-1 and anti-apoptotic protein Bcl-2 sug-
gests that HAX-1 is served as an apoptotic arrestin to
participate in regulating apoptosis(namely programmedwith 10% neutral buffered formalin, embedded in paraffin, and
AX-1 staining is strong positive in ESCC samples (400×); Figure 1B:
staining is weakly positive in non-neoplastic samples (200×).
Table 2 Expressions of HAX-1 protein in ESCC and
non-neoplastic samples
Groups n HAX-1 protein Strong positive
expression rate (%)
P
- + ++ +++
Peri-cancerous samples 112 0 61 51 0 0.00 P = 0.000
ESCC samples 112 0 9 52 51 45.54
Age(yr)
≥60 50 0 3 24 23 46.00 P = 0.929
<60 62 0 6 28 28 45.16
Gender
Male 50 0 3 25 22 44.00 P = 0.769
Female 62 0 6 27 29 46.77
Lymph node metastasis
Yes 45 0 0 13 32 71.11 P = 0.000
No 67 0 9 39 19 28.36
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endocytosis. It has been reported that HAX-1 silencing
could induce melanoma cell apoptosis [20], suggesting
that HAX-1 plays an important role in tumorigenesis and
tumor metastasis [21]. Many molecules are involved in the
metastasis of ESCC, such as ABCG2/V-ATPase [22].
Little research has been done on HAX-1 protein ex-
pression in ESCC samples. Previous studies of our teamFigure 2 The follow-up data was analyzed by the Kaplan-Meier meth
Schematic representation shows survival curves of lymph node metastatic
Schematic representation shows survival curves of different protein level gr
shows survival curves of different sexes in patients with ESCC. Figure 2D: S
patients with ESCC. Log-rank test indicated that there were significant diffe
non-metastatic group (χ2 = 19.484, P = 0.000, Figure 2A), and among group
Figure 2B); but no significant differences between male patients and femal
patients and <60 years old patients (χ2 = 0.143, P = 0.705, Figure 2D).found that HAX-1 promotes the proliferation, chemo-
resistance, invasion, and tumorigenicity of ESCC, and
this is correlated with increased DNA polymerase β ex-
pression. HAX-1 may represent a potential target to
overcome the resistance and metastasis of ESCC [23].
This study confirmed the presence of HAX-1 over-
expression in ESCC samples for the first time. The expres-
sion level of HAX-1 mRNA and the strong positive rate of
HAX-1 protein expression were significantly higher in
ESCC samples (0.527 ± 0.060 and 45.54%) than that in
non-neoplastic samples (0.121 ± 0.017 and 0.00%), and in
ESCC samples with lymph node metastasis (0.5540 ± 0.054
and 71.11%) than that in ESCC samples without lymph
node metastasis (0.509 ± 0.058 and 28.36%) (all P < 0.01).
The expression level of HAX-1 mRNA was positively cor-
related with lymph node metastasis, and was a risk factor
of lymph node metastasis in the patients with ESCC (Wald
χ2 = 12.743, P = 0.000). There were significant differences in
survival curves between lymph node metastatic group and
non-metastatic group (χ2 = 19.484, P = 0.000), and among
groups of HAX-1 protein expression +, ++ and +++(χ2 =
80.729, P = 0.000); but no significant differences between
male patients and female patients (χ2 = 2.435, P = 0.119),
and between ≥60 years old patients and <60 years oldod and log-rank test. The survival curves were made. Figure 2A:
group and non-metastatic group in patients with ESCC. Figure 2B:
oups in patients with ESCC. Figure 2C: Schematic representation
chematic representation shows survival curves of different ages in
rences in survival curves between lymph node metastatic group and
s of HAX-1 protein expression +, ++ and +++ (χ2 = 80.729, P = 0.000,
e patients (χ2 = 2.435, P = 0.119, Figure 2C), and between ≥60 years old
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(Wald χ2 = 55.641, P = 0.000) and protein (Wald χ2 =
0.7.929, P = 0.005) were risk factors of survival, but lymph
node metastasis (Wald χ2 = 0.506, P = 0.477) was not a risk
factor of survival in the patients with ESCC. These results
suggest that there is HAX-1 over-expression in ESCC sam-
ples and the level of HAX-1 mRNA is a risk factor of lymph
node metastasis and survival in the patients with ESCC.
The results may provide a basis for exploring the role of
HAX-1 in ESCC. The expression level of HAX-1 is
expected to become an important index to assess ESCC in-
vasion and metastasis, and prognosis of patients with
ESCC. HAX-1 may be a novel therapeutic target for ESCC
treatment.
Conclusion
In conclusion, our data offer the convincing evidence
that there is HAX-1 over-expression in ESCC tissue and
the level of HAX-1 mRNA is a risk factor of lymph node
metastasis. The level of HAX-1 mRNA and protein are
risk factors of survival in patients with ESCC. HAX-1
may be a novel therapeutic target for ESCC treatment.
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